NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

脊髓性肌萎縮症(SMA):流行病學的預測(2027年)

Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 534997
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 2-10個工作天內
價格
脊髓性肌萎縮症(SMA):流行病學的預測(2027年) Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

主要7個國家脊髓性肌萎縮症(SMA)的整體罹患數,2017年推定為3萬8,900人。

本報告提供脊髓性肌萎縮症(SMA)的相關調查,總括性彙整疾病概要,患者背景,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的罹患數趨勢,今後10年流行病學的預測,成長要素及市場障礙,今後市場機會等資訊。

目錄

第1章 報告概要

第2章 脊髓性肌萎縮症(SMA):背景和概要

  • 簡介
  • 分類
  • 原因
  • 病理生理學
  • 症狀
  • 診斷

第3章 流行病學和患者人口

  • 患者人口與預測參數
  • 重要點
  • 主要7個國家的脊髓性肌萎縮症(SMA)患病數
  • 主要7個國家的脊髓性肌萎縮症(SMA)診斷診斷數(實際成果值)
  • 主要7個國家的脊髓性肌萎縮症(SMA)診斷患者數(預測值)
  • 美國
    • 脊髓性肌萎縮症(SMA)診斷患者數
  • 歐盟5國
    • 德國
      • 脊髓性肌萎縮症(SMA)診斷患者數
    • 法國
      • 脊髓性肌萎縮症(SMA)診斷患者數
    • 英國
      • 脊髓性肌萎縮症(SMA)診斷患者數
    • 西班牙
      • 脊髓性肌萎縮症(SMA)診斷患者數
    • 義大利
      • 脊髓性肌萎縮症(SMA)診斷患者數
  • 日本
    • 脊髓性肌萎縮症(SMA)診斷患者數

第4章 附錄

第5章 調查手法

第6章 諮詢服務

第7章 免責聲明

第8章 關於DelveInsight

目錄
Product Code: DIEI0223

DelveInsight's "Spinal Muscular Atrophy (SMA) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Spinal Muscular Atrophy (SMA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Spinal Muscular Atrophy (SMA) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Spinal Muscular Atrophy (SMA) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Spinal Muscular Atrophy (SMA) outlook. It also includes the explanation of changing trends of epidemiology outlining the Spinal Muscular Atrophy (SMA) scenario.

Spinal Muscular Atrophy (SMA) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Spinal Muscular Atrophy (SMA) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Spinal Muscular Atrophy (SMA) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Spinal Muscular Atrophy (SMA) Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Spinal Muscular Atrophy (SMA)

Key assessments

  • Patient Segmentation in Spinal Muscular Atrophy (SMA)
  • Spinal Muscular Atrophy (SMA) Risk & Burden
  • Factors driving growth in a specific Spinal Muscular Atrophy (SMA) patient population

Table of Contents

1. Report Introduction

2. Spinal Muscular Atrophy (SMA) Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Spinal Muscular Atrophy (SMA) in 2016
  • 2.2. Patient Share Distribution of Spinal Muscular Atrophy (SMA) in 2028

3. Disease Background and Overview: Spinal Muscular Atrophy (SMA)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Spinal Muscular Atrophy (SMA) in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Spinal Muscular Atrophy (SMA) in 7MM - By Countries

5. Epidemiology of Spinal Muscular Atrophy (SMA) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.1.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.1.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.1.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.4.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.4.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.4.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.5.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.5.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.5.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.6.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.6.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.6.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.7.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.7.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.7.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.8.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.8.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.8.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA)
    • 5.9.3. Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) *
    • 5.9.4. Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) *
    • 5.9.5. Diagnosed Cases of the Spinal Muscular Atrophy (SMA)

6. Unmet Needs of the Spinal Muscular Atrophy (SMA)

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Spinal Muscular Atrophy (SMA) in Japan (2016-2028)